A presentation on my life in public health and vaccinations- from measles in the West Midlands of England, 1983-2014 to COVID-19 in Europe, 2020-now, implications for the public health community and vaccines manufactures including the vaccine TRIPS waiver. Presentation to a Spanish public health and vaccines forum, October 18th 2021 211018 middleton spanish vaccines and industry presentation 1 version recorded
This important presentation encompasses all the vaccines of COVID at current point of time; it's mechanism of action, its efficacy data's and advantages and disadvantages
This important presentation encompasses all the vaccines of COVID at current point of time; it's mechanism of action, its efficacy data's and advantages and disadvantages
Public perception on COVID-19 Vaccine(AstraZeneca) uptake presentation-Simon ...SimonMwaringa
Public Perception on Covid-19 ( AstraZeneca) Uptake at University of Eldoret: a case study at University of Eldoret.
2. Coronaviruses: from Animals to Humans
3. Covid-19: How does it affect you?
4. The pandemic "vaccine" development
5. Vaccine Devpt against SARS-CoV-2
6. How two types of COVID-19 Vaccine Work
7. Key features of the spike protein
8. Testing Vaccines
9. An array of Vaccines
10. Perception
11. Justification
12. Objectives
*General Objectives
*Specific Objectives
13. Research Questions
14. Materials and Methods
15. Demographic Characteristic of Respondents
16. Ratio of Male to Female Willingness for COVID-19 Vaccine
17. Immunization Centre Awareness
18. Vaccine Knowledge from Respondents
19. Public Trust in Government's choice of Vaccine
20. Public Trust in Pharmaceutical Companies
21. Vaccination Status of Respondents
22. Influence of Vaccine Uptake by Religious Leaders
23. Safety Concerns towards COVID-19 Vaccine
24. Conspiracies
25. Do you believe in the Conspiracy Theories
26. Conclusion
27. Recommendation
28. End
A teaching aid on addressing hesitancy to Covid-19 vaccination. WHO has identified vaccine hesitancy as a major threat to global health. Learn more about how to work with patients, the public and communities to improve confidence in Covid-19 vaccines.
COVID 19 Team-Based Approaches to Patient PopulationsCHC Connecticut
As presented as part of The Path Forward on Jan 28, 2021:
Stable housing and health outcomes are inextricably linked. When a patient loses housing – or is in jeopardy of losing housing– health outcomes suffer. COVID has led us to a moment of crisis. Thirty million to 40 million people in the United States face eviction. People of color are disproportionately impacted. Addressing housing as a social determinant of health is critical to achieving health equity. This webinar brings together experts from housing, healthcare and the intersection of both to share innovative short- and long-term solutions you can implement in your community.
Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring in US history. VITAS Healthcare offer an educational presentation for our partner organizations to use for their own in-house or staff training.
The Latest on COVID19 & The Promise of the COVID19 Vaccine: A Pediatrician's...Katherine Noble
1) Where we were (March 2020)
2) Where we are (March 2021)
3) Where we are heading
- The promise of the COVID19 vaccine
- COVID19 vaccines for children
- Approaching vaccine hesitancy
Antibiotic resistance: causes, consequences and means to limit itGreenFacts
Over the last century, antibiotics have radically changed the
way we treat infections. They are an important tool for modern medicine, but unfortunately their misuse have led to the emergence of bacteria that are resistant to antibiotics.
What has caused it and how can the spread of resistance be limited?
Safety and Success in a Post-Pandemic Society - Daniela Accurso, MD, MPH - 7...Summit Health
The Covid-19 Pandemic has been a health crises that we have been fighting for the last year and a half. Dr. Accurso’s presentation is focused on reviewing how far we have come as a society and to address the questions, health concerns, and important precautions we need to take as we integrate ourselves back into a healthy community.
The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4] The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020.[5] As of 25 March, more than 422,000 cases of COVID-19 have been reported in more than 190 countries and territories, resulting in more than 18,900 deaths and more than 109,000 recoveries.
Presentation to the Norfolk Medical and Surgical Society, January 21st 2022 on the current state of the pandemic worldwide and in the UK and other global and planetary threats to health and how to 'plan for an outbreak of health'
20220125middleton medchi
Public perception on COVID-19 Vaccine(AstraZeneca) uptake presentation-Simon ...SimonMwaringa
Public Perception on Covid-19 ( AstraZeneca) Uptake at University of Eldoret: a case study at University of Eldoret.
2. Coronaviruses: from Animals to Humans
3. Covid-19: How does it affect you?
4. The pandemic "vaccine" development
5. Vaccine Devpt against SARS-CoV-2
6. How two types of COVID-19 Vaccine Work
7. Key features of the spike protein
8. Testing Vaccines
9. An array of Vaccines
10. Perception
11. Justification
12. Objectives
*General Objectives
*Specific Objectives
13. Research Questions
14. Materials and Methods
15. Demographic Characteristic of Respondents
16. Ratio of Male to Female Willingness for COVID-19 Vaccine
17. Immunization Centre Awareness
18. Vaccine Knowledge from Respondents
19. Public Trust in Government's choice of Vaccine
20. Public Trust in Pharmaceutical Companies
21. Vaccination Status of Respondents
22. Influence of Vaccine Uptake by Religious Leaders
23. Safety Concerns towards COVID-19 Vaccine
24. Conspiracies
25. Do you believe in the Conspiracy Theories
26. Conclusion
27. Recommendation
28. End
A teaching aid on addressing hesitancy to Covid-19 vaccination. WHO has identified vaccine hesitancy as a major threat to global health. Learn more about how to work with patients, the public and communities to improve confidence in Covid-19 vaccines.
COVID 19 Team-Based Approaches to Patient PopulationsCHC Connecticut
As presented as part of The Path Forward on Jan 28, 2021:
Stable housing and health outcomes are inextricably linked. When a patient loses housing – or is in jeopardy of losing housing– health outcomes suffer. COVID has led us to a moment of crisis. Thirty million to 40 million people in the United States face eviction. People of color are disproportionately impacted. Addressing housing as a social determinant of health is critical to achieving health equity. This webinar brings together experts from housing, healthcare and the intersection of both to share innovative short- and long-term solutions you can implement in your community.
Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring in US history. VITAS Healthcare offer an educational presentation for our partner organizations to use for their own in-house or staff training.
The Latest on COVID19 & The Promise of the COVID19 Vaccine: A Pediatrician's...Katherine Noble
1) Where we were (March 2020)
2) Where we are (March 2021)
3) Where we are heading
- The promise of the COVID19 vaccine
- COVID19 vaccines for children
- Approaching vaccine hesitancy
Antibiotic resistance: causes, consequences and means to limit itGreenFacts
Over the last century, antibiotics have radically changed the
way we treat infections. They are an important tool for modern medicine, but unfortunately their misuse have led to the emergence of bacteria that are resistant to antibiotics.
What has caused it and how can the spread of resistance be limited?
Safety and Success in a Post-Pandemic Society - Daniela Accurso, MD, MPH - 7...Summit Health
The Covid-19 Pandemic has been a health crises that we have been fighting for the last year and a half. Dr. Accurso’s presentation is focused on reviewing how far we have come as a society and to address the questions, health concerns, and important precautions we need to take as we integrate ourselves back into a healthy community.
The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4] The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020.[5] As of 25 March, more than 422,000 cases of COVID-19 have been reported in more than 190 countries and territories, resulting in more than 18,900 deaths and more than 109,000 recoveries.
Presentation to the Norfolk Medical and Surgical Society, January 21st 2022 on the current state of the pandemic worldwide and in the UK and other global and planetary threats to health and how to 'plan for an outbreak of health'
20220125middleton medchi
Alhajji 1
Alhajji 6
JafarAlhajji
Professor:
English homework
May 1, 2019
Vaccines safety and effectiveness
Do you think vaccination is an important or just harmful substance forced by pharmaceutical companies cooperating with the governments to inject into people? A vaccine can be defined as "biological preparations that, when introduced into the body, cause an individual to acquire immunity to a specific disease” (Davidson. 7). So, for decades, vaccines have been considered one of the best revaluation in medical practice. A long time ago, people all around the world tried to fight with different kinds of fatal diseases by different ways, and one of the most Significant ways is to make a vaccine, to prevent such life-threatening diseases. The first vaccine was against the Smallpox disease. Smallpox is a highly contagious disease and caused a lot of fatalities all around the world, and it is transmitted between people by inhalation of droplets of virus or direct contact with smallpox lesion secretions (Davidson 25). It is a deadly disease, it caused blindness and permanent scars in the patients that survived. Finally, after several attempts to make a vaccine for Smallpox, Edward succeeded to produce an effective and safe vaccine in 1796 by using the cowpox vaccine to protect from smallpox. Cowpox is a disease caused by cows and transferred to a human, and Jenner's theory was based that whoever had cowpox will be immunized against smallpox (Davidson29).“Edward Jenner was an English country doctor who introduced the vaccine for smallpox. Previously a keen practitioner of smallpox inoculation.”
Then, century after century, the vaccine after the vaccine was developed for different kinds of diseases. In the 20th century, one of the most known vaccines was Diphtheria and Tetanus vaccines. Diphtheria is a respiratory illness, causing the release of exotoxin from Corynebacterium diphtheria bacteria which leads to the death of mucous cells in the throat, mouth, and nose, and as a result of cells accumulation the pseudo-membrane are build up and block the airways of the patients which causes death (Davidson42) After years of experiments and trials to make a vaccine to fight this disease, Gaston Ramona French veterinarian and biologist who realized that attenuated Diphtheria toxin is able to activate the immune system of people without causing serious side effects, and by 1927, the toxoid vaccine was freely used all around the world, and it succeeds to drop the number of cases of diphtheria. Then, by using the same way of toxoid, combined Diphtheria and Tetanus Toxoid vaccines were produced. Tetanus can be described as a nerves system infection that leads to spasm and contract of body muscles, especially jaw muscles which make the patients unable to open their mouths (Davidson. 44)
Another example of one of the most significant vaccine is a Polio vaccine. Polio disease, mainly affecting children under 5 years old, and leading to paralysis and often to .
Antibiotic Guardian Leeds Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
Big sky thinking: leadership for public health from the East of England John Middleton
Presentation to the first East of England Public Health conference, Radison Hotel, Stagnated. 30th October 2018 181029 east of england presentation vr 2
COVID-19: What went right, what went wrong and how do we learn from this? John Middleton
Look at UK English and European experience during the COVID-19 pandemic. Successes and failures. Presentation for a meeting of the Centre for Health and Development (CHAD) University of Staffordshire. Centre via recorded lecture, Thursday, 28 October 2021 12:00 211027 4 definitive middleton chad conference final
Video presentation also to be available online
In this topic take about public health microbiology because of people are not aware about virus or disease vaccine is more essential for human being save our lives from the virus it is major requirements for people
The Life After COVID-19: A Frontliner's Perspective.MaMonicaRivera
These slides are uploaded for information and as partial requirement of Philippine Women's University in Master of Nursing (MAN); Subject: Nursing Practicum
By: Ma. Monica Rivera, BSN, RN
Planning for an outbreak of health? Lessons from the COVID-19 pandemicJohn Middleton
Planning for an outbreak of health? Lessons from the COVID-19 pandemic Presentation to a meeting of the Alliance International Science Organisations,Univversity fo Belgrade and Chinese Academy of Sciences, online, September 23rd 2021
210923 middletonj anso conference beograd
20240412 middletonj ASPHER war curriculum.pptxJohn Middleton
A short presentation for the ASPHER webinar, for Global Public Health Week 73. ASPHER’s Core Curriculum Programme (CCP): what are the needs for teaching the role of public health in preventing and responding to armed conflict?
Prevention, Recovery, Rehabilitation
A life in public health, influences and chunesJohn Middleton
A presentation for the Associaiton of Schools of public Health in the European Region, ASSETS summer school, Brussels, July 3-6th 2023. covering a career in public health, major influences on my practice, and musical references to public health 20230711 middletonj assets very final.pptx
A healthy state? Geopolitical threats to safety and health John Middleton
A presentation to the first European conference of Law Enforcement and Public Health, Umea Sweden, May 22nd-24th 2023; on geopolitical trends and concerns for policing and public health improvement
20230625 middletonj LEPH UMEA healthy State delivered presentation.pptx
A presentation for the ASPHER and University of Bielefeld in the series, 'Public Health in the Times of War '
20221125-4.5 final delivered militarism and health.pptx
20221125-4.5 final delivered militarism and health.pptx
The perspective on Public Health Curricula Accreditationand international r...John Middleton
A presentation on the work of ASPHER the Association of Schools of public Health in the European Region, and APHEA, the Agency for Public Health Education Accreditation, for the congress National Des Medicine Saude Public (Portugal, November 3rd 2022)
ASPHER's ambition in climate change and health educationJohn Middleton
A presentation for the launch of the ASPHER Climate change and health education EU Health Policy Platform network 202207 ASPHER middletonj climate change and health long version.pptx
Climate change as a high risk factor for health John Middleton
Presentation for the World Committee for lifelong learning (CMA) 4th conference debate at the Cite Des Metiers, Paris, June 22nd 2022
20220622 CMA middletonj climate change and health long version.pptx
Planning for an outbreak of health? Lessons from the COVID-19 pandemicJohn Middleton
Presentation for Jagellonian University Krakov, Poland, Institute of Public Health 30th anniversary celebration congress, October 708th 2021. 211007 middletonj krakow vr 2
Presentation for the Grand European Symposium: Training, Research and Innovation in the Europe of Health”, on September 30th 2021, The Sorbonne Grand Amphitheater
210923 middletonj sorbonne vr2
Die Zukunft ist rosig, die Zukunft ist die öffentliche GesundheitJohn Middleton
The future's bright, the future is public health. Presentation to the MPH students introductory course Bielefeld University School of public Health, October 11th 2021. 211011 2 middleton j bielefeld main
The best job in the world: A past, and a future in public health John Middleton
A description of my career in public health today including lessons from local, national and international public health and the current COVID-19 pandemic. Presentation for the Coventry University BSc in public health employability course, October 25th 2021.
211025 middleton coventry final
The urgent need to train students to be global advocates and activists : plan...John Middleton
Presentation for the Escuela de Salud Pública de México (ESPM), part of the Instituto Nacional de Salud Pública (INSP). 100 year celebration, April 22nd 2021. INSP210422 middletonj insp vr3
A review of global health issues, highlighted by the COVID-19 pandemic and suggestions for improvement of health in a post pandemic world. Presentation for the Mongolian National University of Medicine School of public Health, April 16th 2021
210415 long version middleton j mongolia ph conference
Presentation for the Associação de Estudantes da Escola Nacional de Saúde Pública da Universidade NOVA de Lisboa (AEENSP_NOVA) April 20th 2021 210420 long version middleton j aeensp
The best job in the world: practicing public health, past present and futureJohn Middleton
Practicing public health, past present and future. annual lecture to the Maastricht Global Public Health Leadership students course. with an extended additional section on the year 2020 in pandemic and lessons 201211 middletonj maaastricht
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
1. Vaccinations: saving lives in millions
Professor John Middleton
President, the Association of Schools of Public Health in the
European Region
2. Vaccinations: saving lives in millions
Buenos días compañeros, señoras y
señores en este importante foro
español de vacunas y salud pública
3. Vaccinations: saving lives in millions
How should the public health community work with vaccine
manufacturers?
4. How should the public health community work with vaccine
manufacturers?
As partners committed to improving health and saving lives
With complete honesty, we must understand where there are differences and diffulties in delivering
what we each want
Complete transparency in data sharing and science
Being completely unafraid to be critical, in both directions, when either partner is wrong
We should have our disagreements in private and present a united front in public, but there can be
no suggestion of collusion, no thread for conspiracy theories to be founded
This meeting is a space for dialogue, a chance to come together and get our views on the table.
Vaccinations: saving lives in millions
5. Vaccinations: saving lives in millions
In 2007, British Medical Journal
readers voted Vaccination the
fourth most important medical
milestone since 1840
After sanitation, antibiotics and
anaesthesia
https://www.bmj.com/content/334/7585/111.2.full
6. Vaccinations: saving lives in millions
An extraordinary story of success:
Eradication of smallpox
The near eradication of polio
The high levels of protection against childhood
infections
The potential or theoretical eradication of measles,
hepatitis B
The extraordinary, unprecedented, global effort on
COVID-19 vaccines
8. Vaccinations: saving lives in millions
In 2014, the US Centers for Disease Control and Prevention
estimated that the vaccines given to American infants and
children over the past 20 years will prevent 322 million
illnesses, 21 million hospitalizations and 732,000 deaths
over the course of those lifetimes.
9. Vaccinations: saving lives in millions
In my time in service public health in Coventry
and Sandwell in the West Midlands between
1982-2014, there have been a staggering 26
innovations in immunization and vaccination
programmes . I oversaw implementation of
Measles mumps and rubella vaccine, new
schedules for childhood vaccines, Human
papilloma virus, meningococcal vaccines,
shingles vaccine, pneumococcal vaccine, flu
vaccines for adults and children and more…
10. Vaccinations: saving lives in millions
94
95
96 96
93 93
92
94
95 95
94
80
82
83
89 89 89
88
90
91 91 91
70
75
80
85
90
95
100
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
DTP3 MCV2
Percentage of children (%) vaccinated against measles (MCV2), diphtheria,
tetanus and pertussis (DTP3) in the WHO European Region in 2010- 2020
Source:
WHO/UNICE
F Estimates
of National
Immunizatio
n Coverage
11. Vaccinations: saving lives in millions
Vaccine Min coverage% Max coverage% No of countries with less
than 90% vaccination
coverage
DTP3 73 99 6 (of 53)
MCV2 76 99 13 (of 52)
PCV3 60 99 16 (of 40)
HPV 4 99 28 (of 31)
Immunization coverage in WHO European Region countries in 2019
Source: WHO/UNICEF Estimates of National Immunization Coverage
23. Vaccinations: saving lives in millions
Proportion of the population who would refuse COVIOD_19 vaccine if offered it now. Institute of Health
Metrics and Evaluation, March 2021
29. Renew the mandate of the UN and
WHO in global health governance
The new Treaty for pandemic
preparedness
Governance
Transparency and information
sharing
Resources and capacity
New continental/WHO regional
structures with response capacity
Ceded authority to supranational
structures
30. Revised mandate of
ECDC and EMA
Crisis preparedness
and response
New regulation for
pharmaceutical
industry
Europe’s Beating
Cancer plan
31. We can’t afford to ‘wait and see’ : we must invest more in public health protection.
We must not regret tomorrow, not doing what we know we can do today.
Prof Jose M. Martin-Moreno
38. Vaccinations: saving lives in millions
There is no place for intellectual property protection
during a humanitarian crisis
But there must be fair assessment of how industry
should be properly paid for their work and their
products and to protect and ensure investment for
future new life-saving products
39. Vaccinations: saving lives in millions
Science knows no
country, because
knowledge belongs to
humanity, and is the
torch which
illuminates the world.
Louis Pasteur